What is evolocumab biosimilar research grade? Evolocumab (trade name Repatha) is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. The PCSK9 protein targets LDL receptors for degradation. Evolocumab binds to the circulating PCSK9 protein, inhibiting it from binding to the LDLR, in turn preventing PCSK9-mediated LDLR degradation and permitting the LDLR to recycle back to the liver cell surface. By inhibiting the binding of PCSK9 to LDLR, evolocumab increases the number of LDLRs available to clear LDL from the blood, thereby lowering LDL-C levels. Evolocumab biosimilar uses the same protein sequences as the therapeutic antibody evolocumab.
应用类型
Flow cytometry, animal model study
免疫原
Human PCSK9
来源宿主
CHO cells
反应性
Human
保存建议
Store at 4°C 1 month, store at -20°C to -70°C 12 month. protected from prolonged exposure to light. Avoid freeze/thaw cycles.
